Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaica

Allergologia et Immunopathologia

Volumn 31, Issue 2, 2003, Pages 63-69

  Garcia Selles J ^a   Pascual, A ^a   Funes, E ^a   Pagan J A ^a   Lopez J D ^a   Negro, J M ^a   Hernandez J ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DE LA ARRIXACA   (Spain)

Author keywords

Depigmented allergen; Immunotherapy; Parietaria judaica; Polymerized allergen; Rhinitis

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; DEPIGOID; GLUTARALDEHYDE; PARIETARIA JUDAICA EXTRACT; POLLEN ANTIGEN; UNCLASSIFIED DRUG; VACCINE;

ADULT; ADVERSE DRUG REACTION; ALLERGIC RHINITIS; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FLOWER; GOOD CLINICAL PRACTICE; HUMAN; IMMUNOTHERAPY; MALE; PARIETARIA JUDAICA; POLLEN; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SPAIN; SYMPTOM;

EID: 0037697511     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: 10.1157/13045071     Document Type: Article

References (30)

1. D'Amato G, Spieksma FT, Liccardi G, Jager S, Russo M, Kontou-Fili K, et al. Pollen-related allergy in Europe. Allergy 1998; 53:567-78.
2. World-Health-Organization. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy 1998;53(Suppl): 1-42.
3. Grammer LC, Shaughnessy MA, Shaughnessy JJ, Patterson R. Safety and immunogenicity of immunotherapy with accelerated dosage schedules of polymerized grass and ragweed in patients with dual inhalant sensitivity. J Allergy Clin Immunol 1989;83:750-6.
4. Grammer LC, Shaughnessy MA, Suszko IM, Shaughnessy JJ, Patterson R. A double-blind histamine placebo-controlled trial of polymerized whole grass for immunotherapy of grass allergy. J Allergy Clin Immunol 1983;72(5 Pt 1):448-53.
5. Grammer LC, Shaughnessy MA, Finkle SM, Shaughnessy JJ, Patterson R. A double-blind placebo-controlled trial of polymerized whole grass administered in an accelerated dosage schedule for immunotherapy of grass pollinosis. J Allergy Clin Immunol 1986;78:1180-4.
6. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76 (2 Pt 2):397-401.
7. Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf 1994;10:5-17.
8. Berrens L, Gallego MT, Boluda L, Fernández-Caldas E, González L. Complexed flavonoids on pollen protein allergens revealed by uv-spectroscopy and thin-layer chromatography. Allergy 1998;53 (Suppl):56.
9. Nordic-Council-on-Medicines. Registration of allergen preparations. Nordic-guidelines. Prepared by the Nordic Council on Medicines in cooperation with the Drug Regulatory Authorities in Denmark, Finland, Iceland, Norway and Sweden. NLN Publication No. 23 1989; Edn. January:1-36.
10. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 1986;41(2):131-40.
11. Hirst JM. An automatic volumetric spore trap. Annals of Applied Biology 1952;39:257-65.
12. Subiza J, Jerez M, Jimenez JA, Narganes MJ, Cabrera M, Varela S, et al. Allergenic pollen pollinosis in Madrid. J Allergy Clin Immunol 1995;96:15-23.
13. EAACI. Position paper: Allergen standardization and skin tests. The European Academy of Allergology and Clinical Immunology. Allergy 1993;48(14 Suppl):48-82.
14. Youlten LJ. The peak nasal inspiratory flow meter: a new instrument for the assessment of the response to immunotherapy in seasonal allergic rhinitis. Allergol Immunopathol (Madr) 1980;8:344.
15. Wihl JA, Malm L. Rhinomanometry and nasal peak expiratory and inspiratory flow rate. Ann Allergy 1988;61:50-5.
16. Sachs DH, Winn HJ. The use of glutaraldehyde as a coupling agent for ribonuclease and bovine serum albumin. Immunochemistry 1970;7:581-5.
17. Boluda L, Casanovas M, Prieto JL, Fernandez-Caldas E. Determinations of Par j 1 by a competitive enzyme immunoassay using human specific IgE and IgG. Validation by skin prick testing. J Investig Allergol Clin Immunol 1998;8:207-13.
18. European_Pharmacopeia. Allergen Products (1997:1063). Third edition ed; 1997.
19. Casanovas M, Marañón F, Bel I. Comparison of skin-prick test assay and reverse enzyme immunoassay competition (REINA-C) for biological activity of allergens. Clinical and Experimental Allergy 1994;24:134-9.
20. Boluda L, Gallego MT, Gonzalez_Romano ML, Cambra O, Berrens L. Evaluation of the potency of allergenic extracts by inhibition of IgG-antibody binding. Biologicals 1994;22: 171-7.
21. EAACI-Immunotherapy-Subcommittee. Position paper: Immunotherapy. (EAACI) The European Academy of Allergology and Clinical Immunology. Allergy 1993;48(14 Suppl):7-35.
22. Bousquet J, Hejjaoui A, Soussana M, Michel FB. Double-blind, placebo-controlled immunotherapy with mixed grass-pollen allergoids. IV. Comparison of the safety and efficacy of two dosages of a high-molecular-weight allergoid. J Allergy Clin Immunol 1990;85:490-7.
23. Finney DJ. Statistical Methods in Biological Assay. New York: Hafner; 1964.
24. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002;57:297-305.
25. Walker SM, Pajno GB, Lima MT, Wilson DR, Durham SR. Grass pollen immunotherapy for seasonal rhinitis and asthma: a randomized, controlled trial. J Allergy Clin Immunol 2001; 107:87-93.
26. Wihl JA. Methodological aspects of nasal allergen challenges based on a three-year tree pollen immunotherapy study. Allergy 1986;41:357-64.
27. Holmstrom M, Scadding GK, Lund VJ, Darby YC. Assessment of nasal obstruction. A comparison between rhinomanometry and nasal inspiratory peak flow. Rhinology 1990;28:191-6.
28. Gieni RS, Yang X, Kelso A, Hayglass KT. Limiting dilution analysis of CD4 T-cell cytokine production in mice administered native versus polymerized ovalbumin: directed induction of T-helper type-1-like activation. Immunol 1996;87: 119-26.
29. Hayglass KT, Stefura WP. Antigen-specific inhibition of ongoing murine IgE responses. II. Inhibition of IgE responses induced by treatment with glutaraldehyde-modified allergens is paralleled by reciprocal increases in IgG2a synthesis. J Immunol 1991;147:2455-60.
30. Yang X, Gieni RS, Mosmann TR, HayGlass KT. Chemically modified antigen preferentially elicits induction of Th1-like cytokine synthesis patterns in vivo. J Exp Med 1993;178: 349-53.